Autoreactive B-cell elimination by pathogenic IgG specific for the same antigen: Implications for peripheral tolerance

International Immunology

Volumn 20, Issue 10, 2008, Pages 1351-1360

  Ota, Takayuki ^a,c   Aoki ota, Miyo ^a,c   Tsunoda, Kazuyuki ^a   Nishikawa, Takeji ^a   Koyasu, Shigeo ^a,b   Amagai, Masayuki ^a  

^a KEIO UNIVERSITY   (Japan)

^b JAPAN SCIENCE AND TECHNOLOGY AGENCY   (Japan)

^c SCRIPPS RESEARCH INSTITUTE   (United States)

Author keywords

Autoimmunity; B cells; Fas; Skin

Indexed keywords

DESMOGLEIN 3; FAS LIGAND; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; PROTEIN BCL 2; RAG2 PROTEIN;

ANIMAL TISSUE; ARTICLE; B LYMPHOCYTE; BONE MARROW; CD4+ T LYMPHOCYTE; CELL MATURATION; CONTROLLED STUDY; FEMALE; GENE DELETION; GENE INACTIVATION; IMMUNOLOGICAL TOLERANCE; LYMPHOCYTE TRANSFER; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SPLEEN; TRANSGENIC MOUSE; WILD TYPE;

ADOPTIVE TRANSFER; ANIMALS; ANTIGENS, CD95; AUTOANTIGENS; AUTOIMMUNITY; B-LYMPHOCYTES; CYTOTOXICITY, IMMUNOLOGIC; DESMOGLEIN 3; EPITOPES; IMMUNE TOLERANCE; IMMUNOGLOBULIN CLASS SWITCHING; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; MICE; MICE, TRANSGENIC; PEMPHIGUS; SIGNAL TRANSDUCTION;

EID: 52949149409     PISSN: 09538178     EISSN: 14602377     Source Type: Journal    
DOI: 10.1093/intimm/dxn095     Document Type: Article

References (55)

1. Nemazee, D. 2000. Receptor selection in B and T lymphocytes. Annu. Rev. Immunol. 18:19.
2. Nemazee, D. 2006. Receptor editing in lymphocyte development and central tolerance. Nat. Rev. Immunol. 6:728.
3. Kench, J. A., Russell, D. M. and Nemazee, D. 1998. Efficient peripheral clonal elimination of B lymphocytes in MRL/lpr mice bearing autoantibody transgenes. J. Exp. Med. 188:909.
4. Rathmell, J. C., Cooke, M. P., Ho, W. Y. et al. 1995. CD95 (Fas)-dependent elimination of self-reactive B cells upon interaction with CD4+ T cells. Nature 376:181.
5. Watanabe-Fukunaga, R., Brannan, C. I., Copeland, N. G., Jenkins, N. A. and Nagata, S. 1992. Lymphoproliferation disorder in mice explained by defects in Fas antigen that mediates apoptosis. Nature 356:314.
6. Watson, M. L., Rao, J. K., Gilkeson, G. S. et al. 1992. Genetic analysis of MRL-lpr mice: Relationship of the Fas apoptosis gene to disease manifestations and renal disease-modifying loci. J. Exp. Med. 176:1645.
7. Yajima, K., Nakamura, A., Sugahara, A. and Takai, T. 2003. FcgammaRIIB deficiency with Fas mutation is sufficient for the development of systemic autoimmune disease. Eur. J. Immunol. 33:1020.
8. Amagai, M., Klaus-Kovtun, V. and Stanley, J. R. 1991. Autoantibodies against a novel epithelial cadherin in pemphigus vulgaris, a disease of cell adhesion. Cell 67:869.
9. Ahmed, A. R., Wagner, R., Khatri, K. et al. 1991. Major Histocompatibility complex haplotypes and class II genes in non-Jewish patients with pemphigus vulgaris. Proc. Natl Acad. Sci. USA 88:5056.
10. Niizeki, H., Inoko, H., Mizuki, N. et al. 1994. HLA-DQA1, -DQB1 and -DRB1 genotyping in Japanese pemphigus vulgaris patients by the PCR-RFLP method. Tissue Antigens 44:248.
11. Niizeki, H., Inoko, H., Narimatsu, H. et al. 1991. HLA class II antigens are associated with Japanese pemphigus patients. Hum. Immunol. 31:246.
12. Payne, A. S., Ishii, K., Kacir, S. et al. 2005. Genetic and functional characterization of human pemphigus vulgaris monoclonal autoantibodies isolated by phage display. J. Clin. Invest. 115:888.
13. Futei, Y., Amagai, M., Sekiguchi, M., Nishifuji, K., Fujii, Y. and Nishikawa, T. 2000. Conformational eptiope mapping of desmoglein 3 using domain-swapped molecules in pemphigus vulgaris. J. Invest. Dermatol. 115:829.
14. Sekiguchi, M., Futei, Y., Fujii, Y., Iwasaki, T., Nishikawa, T. and Amagai, M. 2001. Dominant autoimmune epitopes recognized by pemphigus antibodies map to the N-terminal adhesive region of desmogleins. J. Immunol. 167:5439.
15. Amagai, M., Tsunoda, K., Suzuki, H., Nishifuji, K., Koyasu, S. and Nishikawa, T. 2000. Use of autoantigen-knockout mice in developing an active autoimmune disease model for pemphigus. J. Clin. Invest. 105:625.
16. Aoki-Ota, M., Tsunoda, K., Ota, T. et al. 2004. A mouse model of pemphigus vulgaris by adoptive transfer of naive splenocytes from desmoglein 3 knockout mice. Br. J. Dermatol. 151:346.
17. Tsunoda, K., Ota, T., Suzuki, H. et al. 2002. Pathogenic autoantibody production requires loss of tolerance against desmoglein 3 in both T and B cells in experimental pemphigus vulgaris. Eur. J. Immunol. 32:627.
18. Kawasaki, H., Tsunoda, K., Hata, T., Ishii, K., Yamada, T. and Amagai, M. 2006. Synergistic pathogenic effects of combined mouse monoclonal anti-desmoglein 3 IgG antibodies on pemphigus vulgaris blister formation. J. Invest. Dermatol. 126:2621.
19. Tsunoda, K., Ota, T., Aoki, M. et al. 2003. Induction of pemphigus phenotype by a mouse monoclonal antibody against the amino-terminal adhesive Interface of desmoglein 3. J. Immunol. 170: 2170.
20. Ota, T., Aoki-Ota, M., Tsunoda, K. et al. 2004. Auto-reactive B cells against peripheral antigen, desmoglein 3, escape from tolerance mechanism. Int. Immunol. 16:1487.
21. Koch, P. J., Mahoney, M. G., Ishikawa, H. et al. 1997. Targeted disruption of the pemphigus vulgaris antigen (desmoglein 3) gene in mice causes loss of keratinocyte cell adhesion with a phenotype similar to pemphigus vulgaris. J. Cell Biol. 137:1091.
22. Shinkai, Y., Rathbun, G., Lam, K. P. et al. 1992. RAG-2-deficient mice lack mature lymphocytes owing to inability to initiate V(D)J rearrangement. Cell 68:855.
23. Gauld, S. B., Benschop, R. J., Merrell, K. T. and Cambier, J. C. 2005. Maintenance of B cell anergy requires constant antigen receptor occupancy and signaling. Nat. Immunol. 6: 1160.
24. Merrell, K. T., Benschop, R. J., Gauld, S. B. et al. 2006. Identification of anergic B cells within a wild-type repertoire. Immunity 25:953.
25. Barnden, M. J., Allison, J., Heath, W. R. and Carbone, F. R. 1998. Defective TCR expression in transgenic mice constructed using cDNA-based alpha- and beta-chain genes under the control of heterologous regulatory elements. Immunol. Cell Biol. 76:34.
26. Takahashi, Y., Ohta, H. and Takemori, T. 2001. Fas is required for clonal selection in germinal centers and the subsequent establishment of the memory B cell repertoire. Immunity 14:181.
27. Lynch, D. H., Watson, M. L., Alderson, M. R. et al. 1994. The mouse Fas-ligand gene is mutated in gld mice and is part of a TNF family gene cluster. Immunity 1: 131.
28. Takahashi, T., Tanaka, M., Brannan, C. I. et al. 1994. Generalized lymphoproliferative disease in mice, caused by a point mutation in the Fas ligand. Cell 76:969.
29. Baatar, D., Olkhanud, P., Sumitomo, K., Taub, D., Gress, R. and Biragyn, A. 2007. Human peripheral blood T regulatory cells (Tregs), functionally primed CCR4+ Tregs and unprimed CCR4-Tregs, regulate effector T cells using FasL. J. Immunol. 178:4891.
30. Venet, F., Pachot, A., Debard, A. L. et al. 2006. Human CD4+CD25+ regulatory T lymphocytes inhibit lipopolysaccharide-induced monocyte survival through a Fas/Fas ligand-dependent mechanism. J. Immunol. 177:6540.
31. Cory, S. 1995. Regulation of lymphocyte survival by the bcl-2 gene family. Annu. Rev. Immunol. 13:513.
32. Katsumata, M., Siegel, R. M., Louie, D. C. et al. 1992. Differential effects of Bcl-2 on T and B cells in transgenic mice. Proc. Natl Acad. Sci. USA 89:11376.
33. Lang, J., Arnold, B., Hammerling, G. et al. 1997. Enforced Bcl-2 expression inhibits antigen-mediated clonal elimination of peripheral B cells in an antigen dose-dependent manner and promotes receptor editing in autoreactive, immature B cells. J. Exp. Med. 186:1513.
34. Strasser, A., Harris, A. W., Corcoran, L. M. and Cory, S. 1994. Bcl-2 expression promotes B- but not T-lymphoid development in scid mice. Nature 368:457.
35. Strasser, A., Whittingham, S., Vaux, D. L. et al. 1991. Enforced BCL2 expression in B-lymphoid cells prolongs antibody responses and elicits autoimmune disease. Proc. Natl Acad. Sci. USA 88:8661.
36. Bourquin, C., Schubart, A., Tobollik, S. et al. 2003. Selective unresponsiveness to conformational B cell epitopes of the myelin oligodendrocyte glycoprotein in H-2b mice. J. Immunol. 171:455.
37. Warren, S. J., Lin, M. S., Giudice, G. J. et al. 2000. The prevalence of antibodies against desmoglein 1 in endemic pemphigus foliaceus in Brazil. Cooperative Group on Fogo Selvagem Research. N. Engl. J. Med. 343:23.
38. Akkaraju, S., Canaan, K. and Goodnow, C. C. 1997. Self-reactive B cells are not eliminated or inactivated by autoantigen expressed on thyroid epithelial cells. J. Exp. Med. 186:2005.
39. Shlomchik, M., Mascelli, M., Shan, H. et al. 1990. Anti-DNA antibodies from autoimmune mice arise by clonal expansion and somatic mutation. J. Exp. Med. 171:265.
40. Shlomchik, M. J., Marshak-Rothstein, A., Wolfowicz, C. B., Rothstein, T. L. and Weigert, M. G. 1987. The role of clonal selection and somatic mutation in autoimmunity. Nature 328:805.
41. Wolfowicz, C. B., Sakorafas, P., Rothstein, T. L. and Marshak-Rothstein, A. 1988. Oligoclonality of rheumatoid factors arising spontaneously in lpr/lpr mice. Clin. Immunol. Immunopathol. 46:382.
42. Pearse, R. N., Kawabe, T., Bolland, S., Guinamard, R., Kurosaki, T. and Ravetch, J. V. 1999. SHIP recruitment attenuates Fc gamma RIIB-induced B cell apoptosis. Immunity 10:753.
43. Apostolou, I., Sarukhan, A., Klein, L. and von Boehmer, H. 2002. Origin of regulatory T cells with known specificity for antigen. Nat. Immunol. 3:756.
44. Jordan, M. S., Boesteanu, A., Reed, A. J. et al. 2001. Thymic selection of CD4+CD25+ regulatory T cells induced by an agonist self-peptide. Nat. Immunol. 2:301.
45. Picca, C. C., Larkin, J., III, Boesteanu, A., Lerman, M. A., Rankin, A. L. and Caton, A. J. 2006. Role of TCR specificity in CD4+ CD25+ regulatory T-cell selection. Immunol. Rev. 212:74.
46. van Santen, H. M.. Benoist, C. and Mathis, D. 2004. Number of T reg cells that differentiate does not increase upon encounter of agonist ligand on thymic epithelial cells. J. Exp. Med. 200: 1221.
47. Gondek, D. C., Lu, L. F., Quezada, S. A., Sakaguchi, S. and Noelle, R. J. 2005. Cutting edge: Contact-mediated suppression by CD4+CD25+ regulatory cells involves a granzyme B-dependent, perforin-independent mechanism. J. Immunol. 174:1783.
48. Grossman, W. J., Verbsky, J. W., Barchet, W., Colonna, M., Atkinson, J. P. and Ley, T. J. 2004. Human T regulatory cells can use the perforin pathway to cause autologous target cell death. Immunity 21:589.
49. Grossman, W. J., Verbsky, J. W., Tollefsen, B. L., Kemper, C., Atkinson, J. P. and Ley, T. J. 2004. Differential expression of granzymes A and B in human cytotoxic lymphocyte subsets and T regulatory cells. Blood 104:2840.
50. Shevach, E. M., DiPaolo, R. A., Andersson, J., Zhao, D. M., Stephens, G. L. and Thornton, A. M. 2006. The lifestyle of naturally occurring CD4+ CD25+ Foxp3+ regulatory T cells. Immunol. Rev. 212:60.
51. Zhao, D. M., Thornton, A. M., DiPaolo, R. J. and Shevach, E. M. 2006. Activated CD4+CD25+ T cells selectively kill B lymphocytes. Blood 107:3925.
52. Veldman, C. M., Gebhard, K. L., Uter, W. et al. 2004. T cell recognition of desmoglein 3 peptides in patients with pemphigus vulgaris and healthy individuals. J. Immunol. 172:3883.
53. Veldman, C., Hohne, A., Dieckmann, D., Schuler, G. and Herti, M. 2004. Type I regulatory T cells specific for desmoglein 3 are more frequently detected in healthy individuals than in patients with pemphigus vulgaris. J. Immunol. 172:6468.
54. Fattorossi, A., Battaglia, A., Buzzonetti, A., Ciaraffa, F., Scambia, G. and Evoli, A. 2005. Circulating and thymic CD4 CD25 T regulatory cells in myasthenia gravis: Effect of immunosuppressive treatment. Immunology 116:134.
55. Balandina, A., Lecart, S., Dartevelle, P., Saoudi, A. and Berrih-Aknin, S. 2005. Functional defect of regulatory CD4(+)CD25+ T cells in the thymus of patients with autoimmune myasthenia gravis. Blood 105:735.